A five-gene methylation signature predicts overall survival of patients with clear cell renal cell carcinoma

Xiao Jing1 | Gang Xu2 | Yu Gong1 | Junlong Li2 | Lingfeng Wu3 | Wei Zhu3 | Yi He3 | Zhongyi Li1 | Shouhua Pan2

Abstract

Background: In this study, we aimed to screen methylation signatures associated with the prognosis of patients with clear cell renal cell carcinoma (ccRCC).

Methods: Gene expression and methylation profiles of ccRCC patients were downloaded from publicly available databases, and differentially expressed genes (DEGs)-differentially methylated genes (DMGs) were obtained. Subsequently, gene set enrichment and transcription factor (TF) regulatory network analyses were performed. In addition, a prognostic model was constructed and the relationship between disease progression and immunity was analyzed.

Results: A total of 23 common DEGs-DMGs were analyzed, among which 14 DEGs-DMGs were obtained with a cutoff value of PCC < 0 and p < 0.05. The enrichment analysis showed that the 14 DEGs-DMGs were enriched in three GO terms and three KEGG pathways. In addition, a total of six TFs were shown to be associated with the 14 DEGs-DMGs, including RP58, SOX9, NF-κB65, ATF6, OCT, and IK2. A prognostic model using five optimized DEGs-DMGs which efficiently predicted survival was constructed and validated using the GSE105288 dataset. Additionally, four types of immune cells (NK cells, macrophages, neutrophils, and cancer-associated fibroblasts), as well as ESTIMATE, immune, and stromal scores were found to be significantly correlated with ccRCC progression (normal, primary, and metastasis) in addition to the five optimized DEGs-DMGs.

Conclusion: A five-gene methylation signature with the predictive ability for ccRCC prognosis was investigated in this study, consisting of CCNB2, CDKN1C, CTSH, E2F2, and ERMP1. In addition, potential targets for methylation-mediated immunotherapy were highlighted.

KEYWORDS

clear cell renal cell carcinoma, immune, methylation, pathway, transcription factor
1 | INTRODUCTION

Renal cell carcinoma (RCC) is a malignant tumor of the urinary system, with an annual incidence rate accounting for 2–3% of all malignant tumors. The incidence rate in males is higher than that in females, with the ratio of males to females being approximately 2:1. Clear cell RCC (ccRCC) is the most common histological subtype of RCC, accounting for more than 70% of all RCC cases. Moreover, its pathophysiological behavior is extremely complex. Approximately 25% of ccRCC patients are first diagnosed in advanced stages and approximately 33% of ccRCC patients show recurrence or metastasis after surgery. Thus, there is an urgent need to develop more effective therapeutic strategies against ccRCC.

Methylation is a first-line biochemical process playing an important role in the transmission of life and essentially involved in DNA and histone modification. Numerous studies have shown that dysregulation of methylation processes (histones and DNA) can result in cancer development. For instance, Botezatu et al. have reported that changes in DNA methylation can lead to the activation of typically silent genes or silencing of generally active genes. Koch et al. have also suggested that cancer-related changes in DNA methylation are promising targets for the development of powerful diagnostic, prognostic, and predictive biomarkers. Moreover, McCabe et al. have validated numerous potential therapeutic targets for cancer, including many that affect histone methylation. As compared to DNA mutations, gene methylation changes are often events that happen early in the process of cellular carcinogenesis. Thus, they can be used as important risk factors for tumor occurrence and as molecular marker for early diagnosis. As such, screening of high-risk groups via methylation detection could improve the accuracy of early diagnoses and provide valuable therapeutic intervention time for patients with tumors. However, few studies have reported methylation signatures that are associated with the prognosis of patients with different stages of ccRCC progression.

In this study, gene expression and methylation profiles were downloaded from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Differentially expressed genes (DEGs) and differentially methylated genes (DMGs) were obtained between primary vs. normal, metastasis vs. normal, and metastasis vs. primary ccRCC samples. Additionally, a prognostic model was constructed and the relationship between disease progression and immunity was analyzed. Consequently, our study highlights the potential implication of novel methylation-related biomarkers for ccRCC progression offering a theoretical basis for efficacious drug development for the same. The systematic workflow of this study is illustrated in Figure 1.

FIGURE 1 The schematic workflow of the study
2 | MATERIALS AND METHODS

2.1 | Data acquisition and preprocessing

The GSE105288 dataset was downloaded from the GEO database, which included two sub-datasets, namely GSE105260 (methylation profiling, 44 samples) and GSE105261 (gene expression profiling, 44 samples), obtained using the Illumina HumanMethylation450 BeadChip and Illumina HumanHT-12 V4.0 expression beadchip detection platforms, respectively. Preprocessed data with methylated beta detection values and standardized gene expression levels were downloaded, and the methylation and gene expression profile of the probe corresponding to the gene information were obtained according to the annotation information for each detection platform.

The data of ccRCC patients with methylated beta detection values and level 3 normalized data of log(FPKM+1.2) expression level based on the Illumina Infinium Human Methylation 450 BeadChip and Illumina HiSeq 2000 RNA Sequencing detection platforms, respectively, were downloaded from TCGA. A total of 333 samples with information regarding methylation and expression levels were obtained, among which 306 samples that had survival prognostic information were used in this study.

2.2 | Identification of DEGs-DMGs

Based on the GSE105261 and GSE105260 datasets, the DEGs and DMGs were screened between primary vs. normal, metastasis vs. normal, metastasis vs. primary using limma package with the threshold of FDR < 0.05, |log₂(FC)| > 2.63. The overlapping DEGs and DMGs were then obtained, and a heatmap was constructed using the "pheatmap" package in R software. The overlapping DEGs were intersected with overlapping DMGs, and the overlapping co-expressed genes were considered to be the common DEGs-DMGs. The Pearson correlation coefficient (PCC) and Spearman's coefficient (Rho) of methylation and expression levels of the common DEGs-DMGs were calculated using the cor.test function in R software. The DEGs-DMGs with cutoff values of PCC < 0 and p < 0.05 were used for further analysis. In addition, the DAVID tool was used to perform gene set enrichment analysis with a cutoff value of p < 0.05.

2.3 | Gene expression trends based on the Mfuzz clustering algorithm

Based on the expression level of DEGs-DMGs with cutoff values of PCC < 0 and p < 0.05, the "Mfuzz" package in R software was used to conduct the change trend analysis of expression patterns for these DEGs-DMGs and the expression trend module gene clustering was obtained. Here, special attention was paid to related genes whose expression levels continued to increase or decrease along with the progression (normal, primary, and metastasis) of ccRCC.

2.4 | Construction of the transcription factor (TF) regulatory network

Based on the expression level of the DEGs-DMGs with a cutoff value of PCC < 0 and p < 0.05, the DAVID tool was then used to screen TFs significantly associated with DEGs-DMGs. Subsequently, the interactions between TFs and DEGs-DMGs were obtained and the TF-DEGs-DMGs regulatory network was built using Cytoscape.

2.5 | Construction of a prognostic model

The data retrieved from TCGA were used to construct a prognostic model. The 306 ccRCC tumor samples from the database were randomly divided into two groups, including the training and validation datasets. Based on the methylation and expression level of the DEGs-DMGs with a cutoff value of PCC < 0 and p < 0.05, the "survival" R package was used to conduct a univariate Cox regression analysis on the training dataset to screen DEGs-DMGs significantly associated with survival prognosis at both methylation and expression levels. p < 0.05 was the criteria for determining prognosis-related DEGs-DMGs. The LASSO regression from the "lars" R package was used to conduct the survival regression analysis to screen the optimized DEGs-DMGs based on the gene methylation levels in the training dataset samples. Moreover, the optimized DEGs-DMGs were verified in the GSE105288 dataset, which included 9 normal, 9 primary, and 26 metastasis samples. Subsequently, a prognostic score (PS) model was established. The formula PS = ΣCoef_\text{genes} × Methylation_\text{genes} (where Coef_\text{genes} represents the LASSO prognostic coefficient of genes and Methylation_\text{genes} represents the gene methylation levels in the training dataset) was used to derive the risk score. The PS was then calculated for the training dataset, validation dataset, and whole groups. The samples were later divided into the low- and high-PS groups using the median PS value. Subsequently, the Kaplan-Meier curve method in the "survival" package was used to compare differences in survival between the low- and high-PS groups. To further understand the correlation between the methylation and expression levels of the optimized DEGs-DMGs screened and survival prognosis, the Kaplan-Meier curve analyses were also performed on the whole dataset. Based on the clinical information of the samples in TCGA dataset, the aov function was used to conduct variance analysis to compare the differences in the distribution of methylation levels of optimized DEGs-DMGs in different clinical groups.

2.6 | Analysis of disease progression and immunity

Based on the genome-wide expression levels obtained in the GSE105261 dataset, the "MCPcounter" R package was utilized to evaluate the level of immune cell infiltration, including eight immune cell types (CD3+ T cells, CD8+ T cells, cytotoxic lymphocytes, NK cells, B lymphocytes, cells originating from monocytes, and myeloid cells).
The differences in the distribution of methylation levels of optimized DEGs with overlapping DMGs led to the identification of 23 common DEGs-DMGs (Figure 2F and Supplementary File S1). The overall correlation between the methylation and expression levels of the 23 common DEGs-DMGs was analyzed, and the results showed that 14 DEGs-DMGs were above the cutoff threshold of PCC < 0 and p < 0.05 (Figure 2G and Supplementary File S2). Further, gene set enrichment analysis showed that the 14 DEGs-DMG were enriched in three gene ontology (GO) terms and three Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (Table 1).

### 3.2 Identification of the DEGs-DMGs with the same expression pattern trends

The “Mfuzz” package in R software was used to conduct the change trend analysis of expression patterns for the DEGs-DMGs, and the expression trend module gene clustering was obtained. The results revealed that the 14 DEGs-DMGs could be clustered into two expression trends categories, with the expression of Cluster 1 being significantly downregulated, while the expression of Cluster 2 continued to be significantly upregulated (Figure 3A). A total of 11 DEGs-DMGs (CAPS, CDKN1C, CKMT1B, CTSH, ERMP1, ERP27, GGT6, GSTM3, KCNJ1, SCNN1A, and STK33) were found in Cluster 1, while Cluster 2 included three DEGs-DMGs (CCNB2, E2F2, and SLFN11).

### 3.3 Construction of the TF regulatory network associated with the 14 DEGs-DMGs

The 14 DEGs-DMGs were subjected to functional annotation using Database for Annotation, Visualization, and Integrated Discovery (DAVID) tools, and a total of six TFs were found to be associated with the 14 identified DEGs-DMGs, including RP58, SOX9, NF-κB65, ATF6, OCT, and IK2 (Table 2). Accordingly, a TF-DEGs-DMGs regulatory network was built using Cytoscape (Figure 3B).

### 3.4 Construction of a ccRCC prognostic model based on five-gene DEG-DMG signature

Based on the univariate Cox regression analysis, a total of seven DEGs and eight DMGs were found to be significantly associated

### Table 1 Enrichment analysis of the 14 DEG-DMRs

| Category       | Term                                                                 | Count | p-Value     | Genes                  |
|----------------|----------------------------------------------------------------------|-------|-------------|------------------------|
| Biology Process| GO:0006749-glutathione metabolic process                           | 2     | 1.43E-02    | GSTM3, GGT6            |
|                | GO:0006508 – proteolysis                                             | 3     | 2.56E-02    | ERMP1, GGT6, CTSH      |
|                | GO:0051726 – regulation of cell cycle                               | 2     | 3.92E-02    | CCNB2, E2F2            |
| KEGG Pathway   | hsa04110:Cell cycle                                                 | 3     | 8.41E-03    | CDKN1C, CCNB2, E2F2    |
|                | hsa04960:Aldosterone-regulated sodium reabsorption                  | 2     | 2.44E-02    | SCNN1A, KCNJ1          |
|                | hsa00480:Glutathione metabolism                                      | 2     | 4.58E-02    | GSTM3, GGT6            |
with prognosis. Moreover, both the methylation and expression levels of seven genes were shown to be significantly associated with prognosis. Thus, these seven DEGs-DMGs were used for further analyses. Based on the seven DEGs-DMGs, five optimized DEGs-DMGs were obtained using the LASSO regression, including CCNB2, CDKN1C, CTSH, E2F2, and ERMP1 (Table 3). Moreover, the five optimized DEGs-DMGs were verified in GSE105288 dataset with the results showing that the gene expression levels of CCNB2 and E2F2 were upregulated with tumor progression, whereas those of CDKN1C, CTSH, and ERMP1 were downregulated. Furthermore, the change trends of these DEGs-DMGs were consistent with the above results (Figure 3C). Subsequently, the five optimized DEGs-DMGs were used to construct a prognostic model. Based on the calculated PS values, the samples were divided into low- or high-PS groups based on the median PS value. In the training, validation, and entire datasets, patients in the low-PS group exhibited significantly longer OS than those in the high-PS group (Figure 4A, D, and G). The predictive ability of the five DEGs-DMGs-based
prognostic model was evaluated subsequently by calculating the area under the curve (AUC) value of the receiver operating characteristic (ROC) curve. The AUC values for the 1-, 3-, and 5-year survival curves in the training, validation, and entire datasets are shown in Figure 4B, E, and H, respectively. The distribution of PS and survival status for the samples was displayed for the training, validation, and entire datasets (Figure 4C, F, and I). Based on the expression and methylation levels, the samples were divided into low- and high-expression or low- and high-methylation based on median expression or methylation levels, respectively. Survival
analysis showed that the expression or methylation level of the five optimized DEGs-DMGs was significantly associated with survival of ccRCC patients (Figure 5). In addition, the differences between the distributions of methylation levels for the five optimized DEGs-DMGs in different clinical groups were evaluated and the results showed that the methylation level of CCNB2 was significantly correlated with pathological M, T, and stage of ccRCC samples (Figure 6A). The methylation level of CDKN1C was also shown to be significantly correlated with age, neoplasm histological grade, and pathological M (Figure 6B). Lastly, the methylation level of ERMP1 was significantly correlated with neoplasm histological grade, pathological T, and tumor stage (Figure 6C).

3.5 Correlation analysis of ccRCC progression with immunity and the five-gene DEGs-DMGs signature

Based on the genome-wide expression levels obtained in the GSE105261 dataset, the “MCPcounter” R package was utilized to evaluate the level of immune cell infiltration. The results of this analysis showed that four immune cell types were significantly correlated with ccRCC progression (normal, primary, and metastatic), which included NK cells, macrophages, neutrophils, and cancer-associated fibroblasts (Figure 7A–D). Moreover, the ESTIMATE, immune, and stromal scores were also found to be correlated with ccRCC progression (normal, primary, and metastasis) (Figure 7E–G). A significant correlation was also found among the four immune cell types, the three scores (ESTIMATE, immune, and stromal score), and the five optimized DEGs-DMGs (Figure 7H).

4 DISCUSSION

Methylation is an important epigenetic modification of proteins and nucleic acids, which plays a crucial role in the regulation of gene expression; however, it is also closely associated with the development of several diseases, such as cancer. In this study, methylation signatures associated with the prognosis of ccRCC patients were evaluated. A total of 23 common DEGs-DMGs were analyzed, among which 14 DEGs-DMGs were above the cutoff threshold of PCC < 0 and p < 0.05. Gene set enrichment analysis showed that the 14 DEGs-DMGs were enriched in three GO terms and three KEGG pathways. In addition, a total of six TFs were shown to be significantly associated with the 14 identified DEGs-DMGs, including RP58, SOX9, NF-xB65, ATF6, OCT, and IK2. Further, a prognostic model which effectively predicted survival of ccRCC patients was constructed using five optimized DEGs-DMGs and then validated using the GSE105288 dataset. Moreover, infiltration of four immune cells types (NK cells, macrophages, neutrophils, and cancer-associated fibroblasts) and the ESTIMATE, immune, and stromal scores were found to be significantly correlated with ccRCC progression (normal, primary, and metastasis). Additionally, the five optimized DEGs-DMGs were also shown to be correlated with the

TABLE 2 Total 6 TFs obtained related to the 14 DEG-DMRs

| Term     | Count | p-Value | Genes                                                                 |
|----------|-------|---------|----------------------------------------------------------------------|
| RP58     | 10    | 1.33E−02| CDKN1C, GSTM3, ERMP1, SLFN11, GGT6, SCNN1A, CKMT1B, E2F2, ERBP27, KCNJ1 |
| SOX9     | 9     | 1.48E−02| CDKN1C, CCNB2, STK33, ERMP1, SCNN1A, CKMT1B, CTSH, E2F2, KCNJ1       |
| NFKAPPAB65 | 5  | 4.61E−02| CDKN1C, GSTM3, STK33, CTSH, KCNJ1                                   |
| ATF6     | 8     | 4.64E−02| CDKN1C, ERMP1, SLFN11, GGT6, SCNN1A, CKMT1B, ERBP27, KCNJ1          |
| OCT      | 8     | 4.70E−02| CDKN1C, STK33, SLFN11, SCNN1A, CKMT1B, CTSH, ERBP27, KCNJ1          |
| IK2      | 6     | 4.74E−02| CDKN1C, GSTM3, CCNB2, GGT6, SCNN1A, CKMT1B                           |

TABLE 3 Five optimized DEG-DMRs obtained using LASSO arithmetic

| ID    | LASSO Coefficient | Methylation level Hazard Ratio (95%CI) | Standard error | Z score | p-value | Expression level Hazard Ratio (95%CI) | Standard error | Z score | p-value |
|-------|-------------------|----------------------------------------|----------------|---------|---------|---------------------------------------|----------------|---------|---------|
| CCNB2 | -0.8117           | 0.080(0.011-0.842)                     | 0.0761         | -2.032  | 4.21E-02| 2.239(1.695-2.958)                    | 0.447          | 5.676  | 2.26E-09|
| CDKN1C| 0.9393            | 2.611(1.025-6.650)                     | 0.00383        | 1.391   | 1.64E-02| 0.784(0.566-0.985)                    | 1.276          | -1.469  | 1.41E-02|
| CTSH  | 6.4132            | 2.482(1.393-25.73)                     | 0.00239        | 1.457   | 1.48E-02| 0.774(0.503-0.911)                    | 1.293          | -1.168  | 2.37E-02|
| E2F2  | -0.2661           | 0.475(0.268-0.798)                     | 0.0211         | -1.240  | 1.98E-02| 4.091(1.779-9.404)                    | 0.245          | 3.317  | 7.54E-04|
| ERMP1 | 1.0382            | 8.876(4.123-70.13)                     | 0.0113         | 4.254   | 1.31E-05| 0.750(0.496-0.913)                    | 1.334          | -1.368  | 1.72E-02|
FIGURE 4 Construction of ccRCC prognostic model with the five-gene DEGs-DMGs signature. The Kaplan-Meier analysis, time-dependent ROC analysis, and risk score analysis for the five optimized DEGs-DMGs for the overall survival of ccRCC patients. (A, B, C) Training dataset. (D, E, F) Validation dataset. (G, H, I) Entire dataset.
infiltration of these four immune cell types and the ESTIMATE, immune, and stromal score.

In this study, we found that the gene expression levels of 14 DEGs-DMGs were significantly correlated with methylation level. Their enrichment analysis showed that the 14 DEGs-DMGs were enriched in three KEGG pathways, including cell cycle, aldosterone-regulated sodium reabsorption, and glutathione metabolism. Cell cycle plays an important role in cancer development. Uncontrolled cell proliferation is a hallmark of carcinogenesis, and tumor cells usually exhibit impairment in genes that directly regulate the cell cycle.\textsuperscript{24} Cell cycle dysregulation via the cyclin D/CDK/pRb pathway is frequently observed in breast cancer, which supports the rationale underlying the development of drugs targeting the cell cycle control machinery.\textsuperscript{25} Hao et al.\textsuperscript{26} have also identified potential biomarkers for ccRCC as being enriched in the aldosterone-regulated sodium reabsorption pathway. Glutathione is a major low-molecular-weight antioxidant, and targeting of the glutathione metabolism is important mechanism associated with anticancer therapies.\textsuperscript{27} Notably, the augmented oxidative stress typically exhibited by cancer cells is also accompanied by an increase in glutathione levels, which confers growth advantages and resistance to a number of chemotherapeutic agents.\textsuperscript{28} A total of six TFs were shown to be associated with the 14 identified DEGs-DMGs, including RP58, S0X9, NF-xB65, ATF6, OCT, and IK2. Some SOX proteins are potential molecular markers of cancer prognosis and are recognized as potential therapeutic targets, including S0X9, S0X2, and S0X4.\textsuperscript{29} NF-xB proteins are key regulators of innate and adaptive immune responses and can accelerate cell proliferation. Notably, increased NF-xB activity is most often observed in solid tumors.\textsuperscript{30} Moreover, higher but non-homogeneous expression of vascular endothelial growth factor is associated with NF-xB 65 activity in ccRCC cells.\textsuperscript{31} ATF6 is one of the three major endoplasmic reticulum stress transducers and has been shown to promote chemotherapy resistance by regulating cancer cell survival.\textsuperscript{32} Few studies have investigated the role of OCT, IK2, and RP58 in ccRCC.

As an important part of this study, we have constructed a prognostic model using five optimized DEGs-DMGs, including CCNB2, CDKN1C, CTSH, E2F2, and ERMP1, which effectively predict survival of ccRCC patients and are verified in GSE105288 dataset. Moreover, the model was verified using an external dataset and was found to have statistical significance. The five DEGs-DMGs used have been reported to be associated with ccRCC progression. For instance, there is evidence that CCNB2 is associated with the prognosis of human cancers, such as RCC,\textsuperscript{33} bladder cancer,\textsuperscript{34} and lung cancer.\textsuperscript{35} Qiu et al.\textsuperscript{36} have shown that chromodomain Y-like promotes chemoresistance in small cell lung cancer by silencing its downstream mediator CDKN1C. Moreover, Na et al.\textsuperscript{37} have reported that IncrRNA STEAP3-AS1 modulates cell cycle progression by affecting CDKN1C expression via STEAP3 in colon cancer. LBX2-AS1 has also been shown to promote ovarian cancer progression by facilitating E2F gene expression via miR-455-5p and miR-491-5p sponging.\textsuperscript{38} Abnormal expression or activation of E2Fs is a common phenomenon in malignant tumors, and E2Fs are significantly correlated with the occurrence or progression of various types of tumors.\textsuperscript{39} Notably, a study by Zhou et al.\textsuperscript{40} has suggested that E2F2/5/8 could serve as a potential prognostic biomarker and target for human ovarian cancer. ERMP1, a novel potential oncogene involved in the unfolded protein response and oxidative stress defense, is highly expressed in human cancers.\textsuperscript{41} In addition, CCNB2 methylation levels were shown to be significantly correlated with pathological M, T, and stage, whereas
FIGURE 6 The differences between the distributions of methylation levels of the five optimized DEGs-DMGs in different clinical groups. (A) CCNB2. (B) CDKN1C. (C) ERMP1

FIGURE 7 Analysis of ccRCC progression and immunity. (A–G) Four immune cell types were found to be significantly correlated with ccRCC progression (normal, primary, and metastasis), including NK cells (A), macrophages (B), neutrophils (C), and cancer-associated fibroblasts (D). The stromal score (E), immune score (F), and ESTIMATE score (G) were shown to be correlated with ccRCC progression. (H) The correlation of the five optimized DEGs-DMGs and the four immune cell types, ESTIMATE score, immune score, and stromal score
the methylation levels of CDKNIC were significantly correlated with age, neoplasm histological grade, and pathological M. Finally, ERMP1 methylation levels were found to be significantly correlated with neoplasm histological grade, pathological T, and stage. These findings further suggest that these five DEGs-DMGs are associated with the development and prognosis of ccRCC and could be used as potential therapeutic targets.

It has been reported that ccRCC is characterized by mutation of the von Hippel-Lindau (VHL) gene in factors governing the hypoxia signaling pathway, resulting in metabolic dysregulation, heightened angiogenesis, intratumoral heterogeneity, and tumor microenvironmental (TME) crosstalk. Thus, we speculated whether crosstalk also occurs between metabolic dysregulation, intratumoral heterogeneity, and TME in ccRCC owing to methylation. The GO functional analysis and KEGG enrichment analysis revealed that these 14 DEGs-DMGs were crucial in functions related to metabolic dysregulation. Moreover, TME is a complex integrated system categorized into the immune microenvironment and non-immune microenvironment. Stromal components dominate the non-immune microenvironment, particularly cancer-associated fibroblasts. Tumor-infiltrating immune cells in the TME have also been shown to critically relate cancer outcomes and play a vital role in tumor immunotherapy. The present study also reports that four immune cell types (NK cells, macrophages, neutrophils, and cancer-associated fibroblasts) and the ESTIMATE, immune, and stromal scores are significantly correlated with ccRCC progression (normal, primary, and metastatic). NK cells are cytotoxic lymphocytes that are part of the innate immune system and are capable of killing virus-infected and/or cancerous cells. Macrophages act as scavengers, modulating the immune response against pathogens and maintaining tissue homeostasis, while tumor-associated macrophages exhibit both anti-inflammatory and pro-tumoral effects. Neutrophils are the first responders to inflammation and infection and respond to diverse inflammatory cues, including cancer development. Finally, cancer-associated fibroblasts, a type of perpetually activated fibroblasts, have been shown to have a strong tumor-modulating effect. In addition, we also found that the five optimized DEGs-DMGs used in our prognostic model significantly correlate with these four immune cell types in addition to the ESTIMATE, immune, and stromal scores. For instance, E2F2 was negatively correlated with NK cells, macrophages, cancer-associated fibroblasts, ESTIMATE score, immune score, and stromal score, while being positively correlated with neutrophils. Thus, the results of this study might reveal crosstalk between metabolic dysregulation and TME in ccRCC owing to methylation. While these findings essentially require further validation, these results also suggested that immunotherapy might serve as an effective treatment strategy for the treatment of ccRCC.

However, our study had some limitations. First, the prognostic model constructed from five optimized DEGs-DMGs was only validated using the GSE105288 dataset; thus, further verification using different datasets is vital. In addition, in vitro and in vivo studies should be performed in order to verify the methylation signatures and to help understand their functional role in ccRCC progression.

5 | CONCLUSION

This study has identified a five-gene methylation signature with significant predictive ability for ccRCC prognosis. In addition, it has highlighted potential targets for methylation-mediated immunotherapy for the treatment of ccRCC. It is imperative for future research to focus on the validation of these findings of this study through pre-clinical studies and clinical trials.

ACKNOWLEDGEMENTS

None.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS

XJ involved in conception and design of the research; GX involved in acquisition of data; YG involved in analysis and interpretation of data; JL and LW involved in statistical analysis; SP involved in drafting the manuscript; YH, ZL, and WZ involved in revision of manuscript for important intellectual content. All authors have read and approved the final manuscript.

CONSENT FOR PUBLICATION

Not applicable.

DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are included in this published article.

ORCID

Shouhua Pan https://orcid.org/0000-0001-6960-8418

REFERENCES

1. Díaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020;16(12):721-735.
2. Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician. 2019;99(3):179-184.
3. Wolf MM, Kimryn Rathmell W, Beckermann KE. Modeling clear cell renal cell carcinoma and therapeutic implications. Oncogene. 2020;39(17):3413-3426.
4. Song E, Song W, Ren M, et al. Identification of potential crucial genes associated with carcinogenesis of clear cell renal cell carcinoma. J Cell Biochem. 2018;119(7):5163-5174.
5. Menezes Y, Clement P, Clement A, Elder K. Methylation: an ineluctable biochemical and physiological process essential for the transmission of life. Int J Mol Sci. 2020;21(23):9311.
6. Botetaztu A, Iancu IV, Plesa A, et al. Methylation of tumor suppressor genes associated with thyroid cancer. Cancer Biomark. 2019;25(1):53-65.
7. Koch A, Jooosten SC, Feng Z, et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncold. 2018;15(7):459-466.
